These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 16356494)

  • 1. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells.
    Watanabe T; Hioki M; Fujiwara T; Nishizaki M; Kagawa S; Taki M; Kishimoto H; Endo Y; Urata Y; Tanaka N; Fujiwara T
    Exp Cell Res; 2006 Feb; 312(3):256-65. PubMed ID: 16356494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ('Telomelysin-RGD').
    Taki M; Kagawa S; Nishizaki M; Mizuguchi H; Hayakawa T; Kyo S; Nagai K; Urata Y; Tanaka N; Fujiwara T
    Oncogene; 2005 Apr; 24(19):3130-40. PubMed ID: 15735729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced antitumor efficacy of telomerase-specific oncolytic adenovirus with valproic acid against human cancer cells.
    Watanabe Y; Hashimoto Y; Kagawa S; Kawamura H; Nagai K; Tanaka N; Urata Y; Fujiwara T
    Cancer Gene Ther; 2012 Nov; 19(11):767-72. PubMed ID: 22956040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Visualization of intrathoracically disseminated solid tumors in mice with optical imaging by telomerase-specific amplification of a transferred green fluorescent protein gene.
    Umeoka T; Kawashima T; Kagawa S; Teraishi F; Taki M; Nishizaki M; Kyo S; Nagai K; Urata Y; Tanaka N; Fujiwara T
    Cancer Res; 2004 Sep; 64(17):6259-65. PubMed ID: 15342413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced transgene expression in urothelial cancer gene therapy with histone deacetylase inhibitor.
    Okegawa T; Nutahara K; Pong RC; Higashihara E; Hsieh JT
    J Urol; 2005 Aug; 174(2):747-52. PubMed ID: 16006969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor effects of telomerase-specific replication-selective oncolytic viruses for adenoid cystic carcinoma cell lines.
    Sato D; Kurihara Y; Kondo S; Shirota T; Urata Y; Fujiwara T; Shintani S
    Oncol Rep; 2013 Dec; 30(6):2659-64. PubMed ID: 24065118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A simple detection system for adenovirus receptor expression using a telomerase-specific replication-competent adenovirus.
    Sasaki T; Tazawa H; Hasei J; Osaki S; Kunisada T; Yoshida A; Hashimoto Y; Yano S; Yoshida R; Kagawa S; Uno F; Urata Y; Ozaki T; Fujiwara T
    Gene Ther; 2013 Jan; 20(1):112-8. PubMed ID: 22241176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telomerase-specific virotheranostics for human head and neck cancer.
    Kurihara Y; Watanabe Y; Onimatsu H; Kojima T; Shirota T; Hatori M; Liu D; Kyo S; Mizuguchi H; Urata Y; Shintani S; Fujiwara T
    Clin Cancer Res; 2009 Apr; 15(7):2335-43. PubMed ID: 19318473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
    Zhang Q; Chen G; Peng L; Wang X; Yang Y; Liu C; Shi W; Su C; Wu H; Liu X; Wu M; Qian Q
    Clin Cancer Res; 2006 Nov; 12(21):6523-31. PubMed ID: 17085667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced antitumor efficacy of telomerase-selective oncolytic adenoviral agent OBP-401 with docetaxel: preclinical evaluation of chemovirotherapy.
    Fujiwara T; Kagawa S; Kishimoto H; Endo Y; Hioki M; Ikeda Y; Sakai R; Urata Y; Tanaka N; Fujiwara T
    Int J Cancer; 2006 Jul; 119(2):432-40. PubMed ID: 16477640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Theranostic application of telomerase-specific oncolytic adenovirus for human cancer].
    Fujiwara T; Tanaka N
    Nihon Rinsho; 2007 Oct; 65(10):1913-22. PubMed ID: 17926546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A histone deacetylase inhibitor enhances adenoviral infection of renal cancer cells.
    Okegawa T; Sayne JR; Nutahara K; Pong RC; Saboorian H; Kabbani W; Higashihara E; Hsieh JT
    J Urol; 2007 Mar; 177(3):1148-56. PubMed ID: 17296436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced adenovirus transgene expression in malignant cells treated with the histone deacetylase inhibitor FR901228.
    Kitazono M; Goldsmith ME; Aikou T; Bates S; Fojo T
    Cancer Res; 2001 Sep; 61(17):6328-30. PubMed ID: 11522619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor effects of telomelysin in combination with paclitaxel or cisplatin on head and neck squamous cell carcinoma.
    Kondo N; Tsukuda M; Kimura M; Fujita K; Sakakibara A; Takahashi H; Ishiguro Y; Toth G; Matsuda H
    Oncol Rep; 2010 Feb; 23(2):355-63. PubMed ID: 20043095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy.
    Höti N; Chowdhury W; Hsieh JT; Sachs MD; Lupold SE; Rodriguez R
    Mol Ther; 2006 Dec; 14(6):768-78. PubMed ID: 16990052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Replication of an adenoviral vector controlled by the human telomerase reverse transcriptase promoter causes tumor-selective tumor lysis.
    Lanson NA; Friedlander PL; Schwarzenberger P; Kolls JK; Wang G
    Cancer Res; 2003 Nov; 63(22):7936-41. PubMed ID: 14633724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retargeting improves the efficacy of a telomerase-dependent oncolytic adenovirus for head and neck cancer.
    Toivonen R; Suominen E; Grenman R; Savontaus M
    Oncol Rep; 2009 Jan; 21(1):165-71. PubMed ID: 19082458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene therapy with secretory leukoprotease inhibitor promoter-controlled replication-competent adenovirus for non-small cell lung cancer.
    Maemondo M; Saijo Y; Narumi K; Kikuchi T; Usui K; Tazawa R; Matsumoto K; Nakamura T; Sasaki K; Takahashi M; Niitsu Y; Nukiwa T
    Cancer Res; 2004 Jul; 64(13):4611-20. PubMed ID: 15231673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct and distant antitumor effects of a telomerase-selective oncolytic adenoviral agent, OBP-301, in a mouse prostate cancer model.
    Huang P; Watanabe M; Kaku H; Kashiwakura Y; Chen J; Saika T; Nasu Y; Fujiwara T; Urata Y; Kumon H
    Cancer Gene Ther; 2008 May; 15(5):315-22. PubMed ID: 18274558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent antitumor effects of combined therapy with a telomerase-specific, replication-competent adenovirus (OBP-301) and IL-2 in a mouse model of renal cell carcinoma.
    Huang P; Kaku H; Chen J; Kashiwakura Y; Saika T; Nasu Y; Urata Y; Fujiwara T; Watanabe M; Kumon H
    Cancer Gene Ther; 2010 Jul; 17(7):484-91. PubMed ID: 20168351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.